Abstract
Five independently evolved classes (α-, β-, γ-, δ-, ζ-) of carbonic anhydrases facilitate the reversible hydration of carbon dioxide to bicarbonate of which the α-class is the most extensively studied. Detailed inhibition studies of the α-class with the two main classes of inhibitors, sulfonamides and metal-complexing anions, revealed many inhibitors that are used as therapeutic agents to prevent and treat many diseases. Recent inhibitor studies of the archaeal β-class (Cab) and the γ-class (Cam) carbonic anhydrases show differences in inhibition response to sulfonamides and metal-complexing anions, when compared to the α-class carbonic anhydrases. In addition, inhibition between Cab and Cam differ. These inhibition patterns are consistent with the idea that although, α-, β-, and γ-class carbonic anhydrases participate in the same two-step isomechanism, diverse active site architecture among these classes predicts variations on the catalytic mechanism. These inhibitor studies of the archaeal β- and γ-class carbonic anhydrases give insight to new applications of current day carbonic anhydrase inhibitors, as well as direct research to develop new compounds that may be specific inhibitors of prokaryotic carbonic anhydrases.
Keywords: glutamine, Pisum sativum, bicarbonate, heterocyclic sulfonamides, Anion Inhibition
Current Topics in Medicinal Chemistry
Title: Inhibition of the Archaeal β-Class (Cab) and γ-Class (Cam) Carbonic Anhydrases
Volume: 7 Issue: 9
Author(s): Sabrina A. Zimmerman, James G. Ferry and Claudiu T. Supuran
Affiliation:
Keywords: glutamine, Pisum sativum, bicarbonate, heterocyclic sulfonamides, Anion Inhibition
Abstract: Five independently evolved classes (α-, β-, γ-, δ-, ζ-) of carbonic anhydrases facilitate the reversible hydration of carbon dioxide to bicarbonate of which the α-class is the most extensively studied. Detailed inhibition studies of the α-class with the two main classes of inhibitors, sulfonamides and metal-complexing anions, revealed many inhibitors that are used as therapeutic agents to prevent and treat many diseases. Recent inhibitor studies of the archaeal β-class (Cab) and the γ-class (Cam) carbonic anhydrases show differences in inhibition response to sulfonamides and metal-complexing anions, when compared to the α-class carbonic anhydrases. In addition, inhibition between Cab and Cam differ. These inhibition patterns are consistent with the idea that although, α-, β-, and γ-class carbonic anhydrases participate in the same two-step isomechanism, diverse active site architecture among these classes predicts variations on the catalytic mechanism. These inhibitor studies of the archaeal β- and γ-class carbonic anhydrases give insight to new applications of current day carbonic anhydrase inhibitors, as well as direct research to develop new compounds that may be specific inhibitors of prokaryotic carbonic anhydrases.
Export Options
About this article
Cite this article as:
Zimmerman A. Sabrina, Ferry G. James and Supuran T. Claudiu, Inhibition of the Archaeal β-Class (Cab) and γ-Class (Cam) Carbonic Anhydrases, Current Topics in Medicinal Chemistry 2007; 7 (9) . https://dx.doi.org/10.2174/156802607780636753
DOI https://dx.doi.org/10.2174/156802607780636753 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Molecular Determinants of Bacterial Diseases)
Current Medicinal Chemistry Synthesis and Antimicrobial Activity of N,N-Bis(2-hydroxylbenzyl)-1,2- ethanediamine Derivatives
Letters in Drug Design & Discovery Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?
Current Medicinal Chemistry - Anti-Infective Agents Managing Febrile Illness in Malaria-endemic Areas: Developing Novel Diagnostics Using Host Immunological Signatures as Surrogate Markers of Infection
Current Immunology Reviews (Discontinued) Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design General Aspects of Two-Component Regulatory Circuits in Bacteria: Domains, Signals and Roles
Current Protein & Peptide Science Anti-cytokines and Cytokines in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Meet Our Editorial Board Member:
Current Medicinal Chemistry Predicting the Impact of Antiretrovirals in Resource-Poor Settings: Preventing HIV Infections whilst Controlling Drug Resistance
Current Drug Targets - Infectious Disorders EDITORIAL: Validation Techniques for Therapeutic Molecules in Drug Discovery
Current Topics in Medicinal Chemistry Biologic Agents for Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis, Characterization, Antitubercular and Anti-Inflammatory Activity of New Pyrazolo[3,4-d]Pyrimidines
Combinatorial Chemistry & High Throughput Screening Chromenopyridines: Promising Scaffolds for Medicinal and Biological Chemistry
Current Medicinal Chemistry Microfluidics as an Emerging Platform for Tackling Antimicrobial Resistance (AMR): A Review
Current Analytical Chemistry Subtracting Gene Function by Gene Silencing and Disruption in Bacteria
Current Biotechnology Development of a Multi-Compartmental Oral Vaccine Delivery System
Drug Delivery Letters Antimicrobial and Biofilm Inhibiting Diketopiperazines
Current Medicinal Chemistry Fabrication and Characterization of Oral Dissolving Films for Tuberculosis Drug Delivery
Nanoscience & Nanotechnology-Asia Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued)